Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV

Vaccine

Volumn 29, Issue 41, 2011, Pages 7188-7196

  Bakker, Wilfried A M ^a   Thomassen, Yvonne E ^a   van't Oever, Aart G ^a   Westdijk, Janny ^a   van Oijen, Monique G C T ^a   Sundermann, Lars C ^b   van't Veld, Peter ^b   Sleeman, Eelco ^c   van Nimwegen, Fred W ^b   Hamidi, Ahd ^a   Kersten, Gideon F A ^a   van den Heuvel, Nico ^b   Hendriks, Jan T ^a   van der Pol, Leo A ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b NETHERLANDS VACCINE INSTITUTE   (Netherlands)

^c Progress PME BV   (Netherlands)

Author keywords

Clinical trial material; Polio eradication; Poliomyelitis; Scale down; Scale up; Vaccine production; Vero cells; Virus seedlots

Indexed keywords

INACTIVATED VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ACTIVE IMMUNIZATION; ARTICLE; BIOENGINEERING; BIOREACTOR; DRUG ANTIGENICITY; DRUG COST; DRUG MANUFACTURE; DRUG SAFETY; ERADICATION THERAPY; GEL PERMEATION CHROMATOGRAPHY; GOOD MANUFACTURING PRACTICE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); POLIOMYELITIS; POLIOMYELITIS VIRUS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; STANDARDIZATION; TECHNOLOGY; VIRUS ATTENUATION; VIRUS INACTIVATION; VIRUS STRAIN; WILD TYPE; WORLD HEALTH ORGANIZATION;

ANIMALS; CELL LINE; HAPLORHINI; HUMANS; NETHERLANDS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; TECHNOLOGY TRANSFER; TECHNOLOGY, PHARMACEUTICAL;

EID: 80052447900     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.079     Document Type: Article

References (67)

1. WHO. Global polio eradication initiative - strategic plan 2010-2012. Available from: [accessed: 04.10.10]. http://www.polioeradication.org/content/publications/GPEI.StrategicPlan.2010-2012.ENG.May.2010.pdf.
2. Kersten G., Hazendonk T., Beuvery C. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 1999, 17:2059-2066.
3. Aylward R.B., Sutter R.W., Cochi S.L., Thompson K.M., Jafari H., Heymann D. Risk management in a polio-free world. Risk Analysis 2006, 26(6):1441-1448.
4. Heymann D.L., Sutter R.W., Aylward R.B. A global call for new polio vaccines. Nature 2005, 434(7034):699-700.
5. Agol V.I. Vaccine-derived polioviruses. Biologicals 2006, 34(2):103-108.
6. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005, 59:587-635.
7. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009, 27(20):2649-2652.
8. Chumakov K., Ehrenfeld E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin Infect Dis 2008, 47(12):1587-1592.
9. John J. Role of injectable and oral polio vaccines in polio eradication. Expert Rev Vaccines 2009, 8(1):5-8.
10. Heinsbroek E., Ruitenberg E.J. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine 2010, 28(22):3778-3783.
11. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper-recommendations. Vaccine 2010, 10.1016/j.vaccine.2010.08.023.
12. Murph J.R, Grose C., Mcandrew P., Mickiewicz C., Mento S., Cano F., Radick L., Ritchey M., Stout M.G. Sabin inactivated trivalent poliovirus vaccine: first clinical trial seroimmunity survey. Pediatr Infect Dis J 1988, 7(11):760-765.
13. Doi Y., Abe S., Yamamoto H., Horie H., Ohyama H., Satoh K., et al. Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev Biol (Basel) 2001, 105:163-169.
14. Simizu B., Abe S., Yamamoto H., Tano Y., Ota Y., Miyazawa M., et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals 2006, 34(2):151-154.
15. Ehrenfeld E., Modlin J., Chumakov K. Future of polio vaccines. Expert Rev Vaccines 2009, 8(7):899-905.
16. Venczel L, Landry S, Aylward B, Sutter R, Sabow A, Smith G. Global post-eradication IPV supply and demand assessment-key findings of the supply landscape and economics of IPV-containing combination vaccines. Oliver Wyman report. March 2009. 23 p. Available from, 2009 [accessed: 04.10.10]. http://www.polioeradication.org/content/publications/SupplyLandscapeEconomics.09.06.2010.pdf.
17. Hickling J, Jones R, Nundy N. Improving the affordability of inactivated poliovirus vaccines (IPV) for use in low- and middle-income countries-an economic analysis of strategies to reduce the cost of routine IPV immunization. PATH and Working in Tandem report. April 2010. 40 p. Available from, 2010 [accessed: 04.10.10]. http://www.polioeradication.org/content/publications/TS_IPV_econ_analysis.pdf.
18. Chinese Academy of Medical Sciences. The clinical trial protocol for the inactivated poliomyelitis vaccine made from Sabin strains (IPV) (Sabin IPV). ClinicalTrials.gov Identifier: NCT01056705. Available from, [accessed: 04.10.2010]. http://clinicaltrials.gov/ct2/show/NCT01056705.
19. Martín J., Crossland G., Wood D.J., Minor P.D. Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. J Gen Virol 2003, 84(7):1781-1788.
20. Dragunsky E.M., Ivanov A.P., Wells V.R., Ivshina A.V., Rezapkin G.V., Abe S., et al. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J Infect Dis 2004, 190(8):1404-1412.
21. Tano Y., Shimizu H., Martin J., Nishimura Y., Simizu B., Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 2007, 25(41):7041-7046.
22. Minor P. Gaps in scientific knowledge for the post eradication world. Biologicals 2006, 34(2):167-170.
23. Baca-Estrada M., Griffiths E. Regulation and standardization of IPV and IPV combination vaccines. Biologicals 2006, 34(2):159-161.
24. Cello J., Paul A.V., Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science 2002, 297(5583):1016-1018.
25. Macadam A.J., Ferguson G., Stone D.M., Meredith J., Knowlson S., Auda G., Almond J.W., Minor P.D. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol 2006, 80(17):8653-8663.
26. Vignuzzi M., Wendt E., Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med 2008, 14:154-161.
27. Jiang S.D., Pye D., Cox J.C. Inactivation of poliovirus with beta-propiolactone. J Biol Stand 1986, 14(2):103-109.
28. Yang C., Shi H., Zhou J., Liang Y., Xu H. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. Vaccine 2009, 27(47):6558-6563.
29. Van Wezel A.L. Growth of cell-strains and primary cells on micro-carriers in homogeneous culture. Nature 1967, 216:64-65.
30. Van Wezel A.L., van Herwaarden J.A., van de Heuvel-de Rijk E.W. Large-scale concentration and purification of virus suspension from microcarrier culture for the preparation of inactivated virus vaccines. Dev Biol Stand 1979, 42:65-69.
31. Van Wezel A.L., van Steenis G., van der Marel P., Osterhaus A.D. Inactivated poliovirus vaccine: current production methods and new developments. Rev Infect Dis 1984, 6(S2):S335-S340.
32. Van Wezel A.L. Monolayer growth systems: homogeneous unit processes. Animal Cell Biotechnology 1985, 1:265-282. Academic Press, London.
33. Duchêne M., Production testing and perspectives of IPV and IPV combination vaccines: GSK biologicals' view. Biologicals 2006, 34:163-166.
34. Montagnon B., Vincent-Falquet J.C., Fanget B. Thousand litre scale microcarrier culture of Vero cells for killed polio virus vaccine. Promising results. Dev Biol Stand 1984, 55:37-42.
35. Vidor E., Meschievitz C., Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 1997, 16(3). 312-222.
36. Van Wezel A.L., van Steenis G., Hannik C.A., Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev Biol Stand 1978, 41:159-168.
37. Duchene M., Peetermans J., D'hondt E., Harford N., Fabry L., Stephenne J. Production of poliovirus vaccines: past, present, and future. Virol Immunol 1990, 3(4):243-272.
38. Van Wezel A.L., van der Velden-de Groot C.A.M. Large scale cultivation of animal cells in microcarrier culture. Process Biochem 1978, 13(3):6-8.
39. Van Hemert P., Kilburn D.G., van Wezel A.L. Homogeneous cultivation of animal cells for the production of virus and virus products. Biotechnol Bioeng 1969, 11(5):875-885.
40. Montagnon B.J., Fanget B., Vincent-Falquet J.C. Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev Inf Dis 1984, 6(S2):S341-S344.
41. Van Wezel A.L., van der Marel P., van Beveren C.P., Verma I., Salk P.L., Salk J. Detection and elimination of cellular nucleic acids in biologicals produced on continuous cell lines. Dev Biol Stand 1981, 50:59-69.
42. Van Wezel A.L., van der Velden-de Groot C.A.M., van Herwaarden J.A. The production of inactivated poliovaccine on serially cultivated kidney cells from captive-bred monkeys. Dev Biol Stand 1980, 46:151-158.
43. Van Wezel A.L. Present state and developments in the production of inactivated poliomyelitis vaccine. Dev Biol Stand 1981, 47:7-13.
44. Van der Velden-de Groot C.A.M. Microcarrier technology, present status and perspective. Cytotechnology 1995, 18:51-56.
45. Bakker WAM, Thomassen YE, van der Pol LA. Scale-down approach for animal-free polio vaccine production. In: T. Noll (editor), Cells and Culture, ESACT Proceedings. Springer, Dordrecht, The Netherlands. 2010; 4(6):541-550.
46. Thomassen Y.E., van Sprang E.N.M., van der Pol L.A., Bakker W.A.M. Multivariate data analysis on historical IPV production data for better process understanding and future improvements. Biotechnol Bioeng 2010, 107(1):96-104.
47. Kreeftenberg H., van der Velden T., Kersten G., van der Heuvel N., de Bruijn M. Technology transfer of Sabin-IPV to new developing country markets. Biologicals 2006, 34:155-158.
48. Oosterhuis NMG. Scale-up of bioreactors: a scale-down approach. PhD thesis. Delft, The Netherlands: Delft University of Technology. Available from; 1984 [accessed: 04.10.10]. http://repository.tudelft.nl/view/ir/uuid:03a887b7-8c20-4052-8d6b-7fe76918d7ec/.
49. Sweere A.P.J., Luyben K.C.A.M., Kossen N.W.F. Regime analysis and scale-down: tools to investigate the performance of bioreactors. Enzyme Microb Technol 1987, 9:386-398.
50. Rathore A., Krishnan R., Tozer S., Smiley D., Rausch S., Seely J. Scaling down of bio-pharmaceutical unit operations. Part 1. Fermentation. Pharm Tech Eur 2006, 4:51-57.
51. Rathore A., Krishnan R., Tozer S., Smiley D., Rausch S., Seely J. Scaling down of bio-pharmaceutical unit operations. Part 2. Chromatography and filtration. Pharm Tech Eur 2006, 7:28-32.
52. Montagnon B.J., Fanget B., Nicolas A.J. The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine. Dev Biol Stand 1981, 47:55-64.
53. EQDM. Vaccines for human use. European Pharmacopoeia 6.3. 01/2009:0153, 3971-3.
54. EQDM, Poliomyelitis vaccine (inactivated). European Pharmacopoeia. 6.7 04/2010:0214, 5608-11.
55. World Health Organization. Recommendations for the production and control of poliomyelitis vaccine (oral). In: WHO Expert Committee on Biological Standardization Fiftieth report, Geneva. 2002; Annex 1 (WHO Tech Rep Series 904):31-93.
56. World Health Organization. Requirements for poliomyelitis vaccine (inactivated). In: WHO Expert Committee on Biological Standardization Fifty-first report, Geneva. 2002; Annex 2 (WHO Tech Rep Series 910):32-65.
57. World Health Organisation. Guidelines for the safe production and quality control of inactivated poliomyelitis vaccine manufactured from wild polioviruses (Addendum, 2003, to the Recommendations for the Production and Quality Control of Poliomyelitis Vaccine (Inactivated)). In: WHO Expert Committee on Biological Standardization Fifty-third report, Geneva. 2004; Annex 2 (WHO Tech Rep Series 926):65-89.
58. Rourou S., van der Ark A., van der Velden T., Kallel H. Development of an animal-component free medium for Vero cells culture. Biotechnol Prog 2009, 25(6):1752-1761.
59. Rourou S., van der Ark A., Majoul S., Trabelsi K., van der Velden T., Kallel H. A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor. Appl Microb Biotechnol 2009, 85(1):53-63.
60. Westdijk J., Brugmans D., Martin J., van't Oever A., Bakker W.A.M., Levels L., Kersten G. Characterization and standardization of Sabin based inactivated polio vaccine. Proposal for a new antigen unit for inactivated polio vaccines. Vaccine 2011, 29(18):3390-3397.
61. Jadhav S., Datla M., Kreeftenberg H., Hendriks J. The developing countries vaccine manufacturers' network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine 2008, 26:1611-1615.
62. Milstien J.B., Gaulé P., Kaddar M. Access to vaccine technologies in developing countries: Brazil and India. Vaccine 2007, 25:7610-7619.
63. Kreeftenberg H, Hamidi A. Lessons learned in the transfer of Hib conjugate vaccine technology and the consequences for access to this vaccine in developing countries. Annex 4 in: WHO Report Intellectual property rights and vaccines in developing countries. 2004;WHO/IVB/04.21.
64. Hong H.A., Ke N.T., Nhon T.N., Thinh N.D., van der Gun J.W., Hendriks J.T., Kreeftenberg J.G. Validation of the combined toxin-binding inhibition test for determination of neutralizing antibodies against tetanus and diphtheria toxins in a vaccine field study in Viet Nam. Bull WHO 1996, 74:275-282.
65. Van Noort R.B. The children's vaccine initiative and vaccine supply: the role of the public sector. Vaccine 1992, 10:909-910.
66. WHO GAPIII. Global action plan to minimize poliovirus facility associated risk after eradication of wild polioviruses and cessation of routine OPV use. Available from [accessed: 08.10.2010]. http://www.polioeradication.org/content/publications/GAPIIIWORKINGDRAFT_07.pdf.
67. Friede M., Serdobova I., Palkonyay L., Kieny M.P. Technology transfer hub for pandemic influenza vaccine. Vaccine 2009, 27(5):631-632.